ITCI SEC Form 4 filings

Intra-Cellular Therapies, Inc. Latest Insider Trading Activity

Over the past 956 days, Intra-Cellular Therapies, Inc. (ITCI) has had 34 total open-market insider transactions represented in the displayed records. The latest displayed record by transaction date reports 5 sales by Mates Sharon (Intra-Cellular Therapies, Inc. Chairman and CEO) totaling 95,925 shares at a weighted-average price of $73.54 per share, with the latest transaction dated August 28, 2024. This page shows up to the 10 most recent SEC Form 4 filing records on a 6-hour delay. Sign up for real-time updates and access to 20 years of historic insider trading data.

Insider Trading For ITCI Charted on Daily Candles. Scroll left or zoom out to load earlier candles (up to 2 years).

▲ Insider buy ▼ Insider sale
Loading daily price history…
Charting by TradingView Lightweight Charts
Ticker Filing Date Transaction Date Company Insider Title Transaction Trade Count Shares Avg. Price Total Value Position Size Change SEC Filing
10b5-1: Scheduled Form 4 Transaction ITCI 2024-08-28 2024-08-28 Intra-Cellular Therapies, Inc. Mates Sharon Chairman and CEO Sell 5 95,925 $73.54 $7,053,850.22 1.76% View Filing
Explained M/S: sale activity tied to share conversions or derivative-related share movements. ITCI 2024-08-20 2024-08-16 Intra-Cellular Therapies, Inc. Neumann Mark EVP, Chief Commercial Officer Sell 1 18,714 $75.08 $1,405,047.12 38.65% View Filing
10b5-1: Scheduled Form 4 Transaction ITCI 2024-03-11 2024-03-11 Intra-Cellular Therapies, Inc. Mates Sharon Chairman, President & CEO Sell 6 61,277 $66.07 $4,048,400.14 0.96% View Filing
10b5-1: Scheduled Form 4 Transaction ITCI 2024-03-11 2024-03-11 Intra-Cellular Therapies, Inc. Neumann Mark EVP, Chief Commercial Officer Sell 5 20,477 $66.23 $1,356,109.71 11.52% View Filing
10b5-1: Scheduled Form 4 Transaction ITCI 2024-02-27 2024-02-26 Intra-Cellular Therapies, Inc. Hineline Lawrence J. SVP of Finance, CFO Sell 5 13,337 $69.43 $925,961.20 62.38% View Filing
10b5-1: Scheduled Form 4 Transaction ITCI 2024-02-27 2024-02-26 Intra-Cellular Therapies, Inc. Neumann Mark EVP, Chief Commercial Officer Sell 4 7,907 $70.13 $554,491.00 5.67% View Filing
10b5-1: Scheduled Form 4 Transaction ITCI 2024-02-05 2024-02-02 Intra-Cellular Therapies, Inc. Halstead Michael EVP and General Counsel Sell 2 11,860 $66.42 $787,719.40 94.32% View Filing
10b5-1: Scheduled Form 4 Transaction ITCI 2024-02-05 2024-02-02 Intra-Cellular Therapies, Inc. Mates Sharon Chairman, President & CEO Sell 2 33,885 $67.07 $2,272,693.50 1.57% View Filing
10b5-1: Scheduled Form 4 Transaction ITCI 2024-02-05 2024-02-02 Intra-Cellular Therapies, Inc. Neumann Mark EVP, Chief Commercial Officer Sell 2 11,860 $67.15 $796,367.48 15.17% View Filing
10b5-1: Scheduled Form 4 Transaction ITCI 2024-02-05 2024-02-02 Intra-Cellular Therapies, Inc. Hineline Lawrence J. SVP of Finance, CFO Sell 2 11,183 $66.62 $745,036.53 98.37% View Filing

Pricing

Free Trial

10 trading days
$0

Explore every Premium feature before you pay.

  • Full platform access
  • 10 trading days
  • No credit card required
  • 20 years of alert history
  • Live alert directory updates
Start your free trial

Standard Monthly

Scheduled
$19.99 / month

Scheduled alerts with complete trade context.

  • Email and Telegram delivery
  • Alert intervals from every sixty minutes to once daily
  • Filter by insider title, buy/sell, transaction value, DRIP, ESPP, 10b5-1, and tax liability coverage transfers
  • Highlighted cluster transactions and SEC filing links
  • Access to the alert directory hourly refreshes
Choose Standard Monthly

Premium Monthly

Recommended
$29.99 / month

Fastest alerts with ticker-level control.

  • Everything in Standard
  • Instant delivery detection-to-outbound time averages 0.90 seconds
  • Alert intervals starting from one minute
  • Real time alert directory updates
Choose Premium Monthly
Student discount: Customers who sign up with a verified .edu email address receive 50% off for the first four years. On monthly plans, the first month is the full 75% off.
Alerts are based on public SEC filings and are provided for informational purposes only; they do not constitute financial advice.